IHL 216A
Alternative Names: IHL-216ALatest Information Update: 07 May 2024
At a glance
- Originator Incannex Healthcare
- Class Anti-inflammatories; Cannabinoids; General anaesthetics; Neuroprotectants
- Mechanism of Action Cell death inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Traumatic brain injuries
Most Recent Events
- 07 May 2024 Phase-I clinical trials in Traumatic brain injuries (Inhalation) (Incannex Healthcare pipeline; May 2024)
- 02 Aug 2022 Incannex Healthcare announces intention to conduct a pre-Investigational New Drug (IND) meeting with the US FDA for IHL 216A, in Q3 2022
- 10 May 2022 Pharmacodynamics data from a preclinical study in Traumatic brain injuries released by Incannex Healthcare